FDA knocks back Novartis copy of Amgen’s drug Neulasta
WASHINGTON: U.S. regulators have declined to approve Novartis' so-called biosimilar copy of Amgen's Neulasta drug… Read More
9 years ago
WASHINGTON: U.S. regulators have declined to approve Novartis' so-called biosimilar copy of Amgen's Neulasta drug… Read More